ANP – Morgans rates the stock as Speculative Buy

Now that Antisense Therapeutics has raised $20m via an institutional placement at $0.24 (along with a 1 for 2 free-attaching options), Morgans raises its target price to $0.58 from $0.45.

The capital allows completion of the Duchenne muscular dystrophy (DMD) program in the EU up to a major valuation inflection point, explains the analyst. A strong pipeline of news catalysts is expected. The Speculative Buy rating is retained.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.


Target price is $0.58.Current Price is $0.23. Difference: $0.35 – (brackets indicate current price is over target). If ANP meets the Morgans target it will return approximately 60% (excluding dividends, fees and charges – negative figures indicate an expected loss).



About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →